Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Tokyo
  • Sector: Health Care
  • Industry: Health Care Facilities & Svcs
  • Sub-Industry: Health Care Services

2191:JP

1,515.0 JPY 18.0 1.20%

As of 02:00:00 ET on 04/21/2015.

Snapshot for tella Inc (2191)

Open: 1,500.0 Day's Range: 1,495.0 - 1,515.0 Volume: 40,000
Previous Close: 1,497.0 52wk Range: 978.0 - 2,187.0 1-Yr Rtn: +11.40%

Stock Chart for 2191

No chart data available.
  • 2191:JP 1,511.0
  • 1D
  • 1M
  • 1Y
1,497.0
Interactive 2191 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 2191

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. TPX -
Earnings Per Share (JPY) (ttm) -29.2600
Est. EPS (JPY) (12/2015) -27.5000
Est. PEG Ratio -
Market Cap (M JPY) 20,899.66
Shares Outstanding (M) 13.80
30 Day Average Volume 57,547
Price/Book (mrq) 8.6443
Price/Sale (ttm) 11.1843
Dividend Indicated Gross Yield -%
Cash Dividend (JPY) -
Dividend Ex-Date 12/28/2015
5 Year Dividend Growth -
Next Earnings Announcement 05/01/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 2191

  • Revenue
  • Net Income (M/JPY)
  • Profit Margin (%)

Company Profile & Key Executives for 2191

tella, Inc. provides cancer treatment and know-hows to contracted medical institutions. The company supports these medical institutions by offering dendritic cell vaccine treatment and other technology that chemical therapy and actinotherapy combined.

Yuichiro YazakiPresident/FounderKunio OhnoDirector
Makoto OhtaDirector
More Company Profile & Key Executives for 2191

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil